10 days past a due dose is 1.43 half-lives at the seven-day half-life this class runs on, which leaves about 37.1 per cent of that dose still circulating. One line of arithmetic: remaining fraction is one half raised to days over half-life, so 0.5^(10÷7) = 0.3715. At 37.1 per cent you have not been off it in any meaningful sense. The interval stretched from 7 days to 17 and the trough went lower than usual; that is the whole of what happened. What the product label says and what the pharmacokinetics say are two different answers here, and the first is the one that governs. Restarting, holding or stepping down after a gap is decided under supervision, and nothing here is medical advice.
Answer first: it depends on the half-life and on how long ago the dose was due, and for a weekly agent the tolerance is much wider than people fear.
With a one-week half-life dosed weekly, missing one dose means exposure falls by about half over the following week — the same trough you would reach if you simply extended the interval. That is well within the range the agent operates in.
For a daily agent with a thirteen-hour half-life, a missed dose is a much larger proportional loss. The usual approach is to skip it and take the next scheduled one rather than doubling.
Loss of tolerance during a treatment gap is documented and is the basis for re-titration after an interruption.
The caveat is that anyone on other glucose-lowering medication has an interaction question here that needs a prescriber.
To move your dosing day, move it later and keep three days between doses.